Clinical Trials Logo

Squamous Cell Carcinoma clinical trials

View clinical trials related to Squamous Cell Carcinoma.

Filter by:

NCT ID: NCT05337163 Completed - Lung Cancer Clinical Trials

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

Start date: February 25, 2022
Phase:
Study type: Observational

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method (includes chest CT examination or pathological examination).

NCT ID: NCT05202860 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma

Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients With Actinic Keratosis

VAXAK
Start date: May 9, 2022
Phase: Phase 2
Study type: Interventional

A double-blind, randomized, placebo controlled intervention trial on patients with actinic keratosis.

NCT ID: NCT05126173 Completed - Clinical trials for Squamous Cell Carcinoma

DERM US and EU Validation Study

Start date: March 15, 2022
Phase:
Study type: Observational

This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the US and European population.

NCT ID: NCT05125354 Completed - Clinical trials for Squamous Cell Carcinoma

A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT

Start date: January 6, 2022
Phase:
Study type: Observational

Evaluation of long-term efficacy outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response.

NCT ID: NCT05108090 Recruiting - Clinical trials for Squamous Cell Carcinoma

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Start date: October 25, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

NCT ID: NCT05104619 Recruiting - Clinical trials for Squamous Cell Carcinoma

Spectroscopic Analysis of Tongue Tumor Samples.

SpecTum
Start date: October 1, 2021
Phase:
Study type: Observational

In squamous cell carcinoma of the tongue, complete surgical resection of the tumor generally represents the primary treatment strategy. Among factors determining the disease prognostic, the surgical margins status is essential for the continued management of the patient, with or without complementary therapies. Generally, surgical margins are defined using visual and tactile elements. Unfortunately, in 15 to 30 percent of cases, they are defined as positive after histopathological examination, on average 5 to 7 days post-surgery. Techniques have recently been developed to analyze the cancerous and non-cancerous nature of tissues, using the spectral properties of tumor cells. SpiderMass™ is an instrument equipped with a probe for tissue micro-sampling and real-time molecular profile analysis. It is thus ultimately a tool for anatomopathological decision support, for diagnosis and prognosis of the disease. Used in the operating room, SpiderMass™ could also become an innovative surgical tool to precisely define cancerous areas in situ and the margins status in intraoperative conditions. Based on the principle of artificial intelligence, the SpiderMass™ machine must initially learn to recognize pathological tissues versus healthy. This project aims to accomplish this first phase of machine learning for squamous cell carcinoma of the tongue.

NCT ID: NCT05070403 Recruiting - Clinical trials for Squamous Cell Carcinoma

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.

NCT ID: NCT05065346 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC

Start date: March 2025
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device (DaRT) as a treatment prior to additional radiation or chemo therapy.

NCT ID: NCT05061537 Terminated - Colorectal Cancer Clinical Trials

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Start date: October 20, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

NCT ID: NCT05048459 Recruiting - Clinical trials for Squamous Cell Carcinoma

Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare standard surveillance with telemedicine surveillance (tele-surveillance) and find out which surveillance approach is best for people with HPV-associated head and neck cancer who have no evidence of disease after treatment. The researches will look at how the two approaches affect participants' quality of life, health outcomes, and expenses (for example, costs of routine visits and procedures). They will also determine doctors' and patients' satisfaction with tele-surveillance.